European perspective for effective cancer drug development
European perspective for effective cancer drug development
复制标题
DOI：
10.1038/nrclinonc.2014.98
复制
发表时间：
2014-08-01
影响因子：
78.8
通讯作者：
Stupp, Roger
中科院分区：
文献类型：
--
作者：
Lacombe, Denis;Tejpar, Sabine;Stupp, Roger
由于风险规避、资助机构的审查和临床试验成本的增加，卫生系统和临床研究格局不断发展。然而，在这种情况下，目前的药物开发程序远非最佳，几种药物的后期失败就是例证。新药的鉴定迫切需要基于对癌症生物学的深入了解的方法，这将支持设计强有力的验证性试验。药物开发的复杂性和成本现在已经超出了单个组织的知识和运营能力，因此，需要从传统的药物发现路径和新形式的多学科合作伙伴关系的急剧偏离，以在这一领域取得成功。欧洲癌症研究和治疗组织（EORTC）提出使用协作分子筛选平台（CMSP）作为解决这一问题的新方法。这些CMSP的优势在于优化了多个合作伙伴的专业知识，并结合成本分担模式，以实现有效的患者选择。本文描述了推进药物开发和改善医疗的一些挑战，以及如何克服这些障碍。
Health systems and the clinical research landscape evolve continuously owing to increased risk aversion, scrutiny by funding bodies, and costs of clinical trials. In this context, however, current drug development procedures are far from optimal, as exemplified by the late-stage failure of several drugs. The identification of new drugs urgently requires approaches based on a solid understanding of cancer biology, and that will support the design of robust confirmatory trials. The complexity and the costs of drug development are now beyond the knowledge and operational capacity of single organisations, therefore, a drastic deviation from the traditional path of drug discovery and new forms of multidisciplinary partnerships are needed to succeed in this sector. The European Organisation for Research and Treatment of Cancer (EORTC) proposes the use of collaborative molecular screening platforms (CMSPs) as a new approach to tackle this issue. These CMSPs have the advantage of optimizing the expertise of several partners and combining efforts alongside with cost-sharing models for efficient patient selection. This article describes some of the challenges to advancing drug development and improving medical treatments and how these hurdles can be overcome.